文献速递腹部MRCT

钆塞酸增强MRI上无动脉期高强化的肝胆期低信号结节的血供增多转化:监测队列的长期随访

Hypervascular transformation of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement on gadoxetic acid-enhanced MRI: long-term follow-up in a surveillance cohort.
PubMed 文献 · Eur Radiol · 2022-02-28

本研究基于382例HCC高危患者的前瞻性监测队列,发现无动脉期高强化的肝胆期低信号结节患病率为12.6%(48/382),中位随访78.6个月后25.0%(19/76)出现血供增多转化,结节≥10 mm是唯一独立预测因素(HR 3.31;95%CI 1.21-9.05)。

要点

  • HCC高危人群监测中,无APHE的HBP低信号结节患病率12.6%。
  • 结节≥10 mm是血供增多转化的唯一独立预测因素(HR 3.31)。
  • ≥10 mm结节5年累积血供增多转化率达50.4%,需密切监测。

核心结论

  • 约半数≥10 mm的无APHE的HBP低信号结节在5年随访内转化为HCC,提示需对这些结节进行加强和延长的谨慎监测。

研究设计与样本

  • 前瞻性收集的纵向监测队列,纳入382例HCC高危患者,接受1-3轮每半年一次的钆塞酸增强MRI监测,随访动态CT和MRI评估结节血供增多转化。

关键影像表现/征象

  • HBP低信号结节在动脉期无高强化,平均大小10.8 mm。
  • 血供增多转化的结节均表现为HCC的典型影像特征。

诊断标准与关键数值

  • 无APHE的HBP低信号结节定义为HBP低信号且动脉期无高强化。
  • 结节≥10 mm预测血供增多转化的HR为3.31(95%CI 1.21-9.05)。
  • ≥10 mm结节12个月和60个月累积转化率分别为12.3%和50.4%。
  • <10 mm结节12个月和60个月累积转化率分别为2.5%和13.9%。

临床应用与阅片要点

  • 对HCC高危患者监测中发现的HBP低信号且无APHE的结节,应测量大小并记录。
  • ≥10 mm的此类结节血供增多转化风险高,作者建议加强和延长随访监测。
  • 随访时应行动态增强CT或MRI以检测血供增多转化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: With the increasing use of gadoxetic acid-enhanced MRI for HCC surveillance, hepatobiliary phase (HBP) hypointense nodules without arterial phase hyperenhancement (APHE) are frequently encountered. We investigated the rate of these nodules with hypervascular transformation, which suggests hepatocarcinogenesis, by using a prospectively collected longitudinal surveillance cohort data.

METHODS: This study included 382 prospectively enrolled patients at high risk for developing HCC who underwent 1-3 rounds of bi-annual surveillance gadoxetic acid-enhanced MRI. MRI was analyzed to detect HBP hypointense nodules without APHE. Follow-up dynamic CTs and MRIs were evaluated to detect hypervascular transformation of the nodules. Cox proportional hazards regression analyses were used to find predictors for hypervascular transformation.

RESULTS: A total of 76 HBP hypointense nodules without APHE were found in 48 patients, giving a prevalence of 12.6% (48/382). The mean nodule size was 10.8 mm, with 43.4% (33/76) being ≥ 10 mm. Over a median follow-up of 78.6 months, 19 nodules (25.0%) showed hypervascular transformation, all of which demonstrated typical imaging features of HCC. On multivariable Cox-regression analysis, size (≥ 10 mm) was the only independent predictor of hypervascular transformation (hazard ratio, 3.31; 95% confidence interval, 1.21-9.05). The cumulative incidence of hypervascular transformation at 12 and 60 months of nodules ≥ 10 mm was 12.3% and 50.4%, respectively, while that of nodules < 10 mm was 2.5% and 13.9%, respectively.

CONCLUSIONS: About half of the HBP hypointense nodules ≥ 10 mm without APHE transformed to HCC at 5 years of follow-up, indicating the necessity for cautious monitoring with an augmented and extended follow-up schedule for these nodules.

KEY POINTS: • The prevalence of HBP hypointense nodules without APHE was 12.6% in a prospectively recruited population at high risk of developing HCC. • Nodule size ≥ 10 mm was significantly associated with hypervascular transformation, and approximately half of the HBP hypointense nodules ≥ 10 mm without APHE transformed to HCC during 5 years of follow-up. • Given the risk of malignant transformation, HBP hypointense nodules ≥ 10 mm without APHE should be closely monitored.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Park, Lee, Kim, et al. Hypervascular transformation of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement on gadoxetic acid-enhanced MRI: long-term follow-up in a surveillance cohort. Eur Radiol. 2022. PMID: 35229195. doi:10.1007/s00330-022-08623-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。